Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.61 |
| ▸ | IGF1R | P08069 | 3/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | JAK1 | P23458 | 3/20 | 0.53 |
| ▸ | JAK2 | O60674 | 2/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.52 |
| ▸ | CDK7 | P50613 | 2/20 | 0.45 |
| ▸ | CCNH | P51946 | 2/20 | 0.45 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.45 |
| ▸ | CCNK | O75909 | 1/20 | 0.45 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 2/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.43 |
| ▸ | JUN | P05412 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29974991 | 0.94 | EGFR (0.63) | EGFRIGF1RKCNH2JAK1JAK2 | |
| SCHEMBL14663383 | 0.94 | EGFR (0.63) | EGFRIGF1RKCNH2JAK1JAK2 | |
| SCHEMBL14663454 | 0.91 | EGFR (0.72) | EGFRIGF1RKCNH2ALKCDK7 | |
| SCHEMBL14663350 | 0.85 | EGFR (0.72) | EGFRIGF1RKCNH2CDK7CCNH | |
| SCHEMBL30998031 | 0.85 | EGFR (0.72) | EGFRIGF1RKCNH2CDK7CCNH | |
| SCHEMBL30956842 | 0.85 | ALK (0.57) | EGFRIGF1RKCNH2JAK1JAK2 | |
| SCHEMBL29232072 | 0.85 | ALK (0.57) | EGFRIGF1RKCNH2JAK1JAK2 | |
| SCHEMBL14663439 | 0.85 | EGFR (0.74) | EGFRIGF1RKCNH2ALKCDK7 | |
| SCHEMBL29974570 | 0.85 | EGFR (0.74) | EGFRIGF1RKCNH2ALKCDK7 | |
| SCHEMBL14718523 | 0.84 | EGFR (0.61) | EGFRIGF1RKCNH2JAK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524951-B2 | 2-(2,4,5-substituted-anilino)pyrimidine compounds | ASTRAZENECA AB (SE) | 2022-12-13 | — | — | US | disclosed |
| US-20210130318-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130318-A1 | 2-(2,4,5-SUBSTITUTED-ANILINO)PYRIMIDINE COMPOUNDS | EGFR, ERBB2, ERBB3 | EGFR 1/4885IGF1R 253/4885KCNH2 2959/4885 |
| US-11524951-B2 | 2-(2,4,5-substituted-anilino)pyrimidine compounds | EGFR, ERBB2, ERBB3 | EGFR 1/4885IGF1R 253/4885KCNH2 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.